

Human CellExp™ 4-1BB / TNFRSF9, Human recombinant

TNFRSF9,4-1BB,CD137,CDw137,ILA Catalog # PBV11471r

Specification

Human CellExp™ 4-1BB / TNFRSF9, Human recombinant - Product info

Primary Accession Calculated MW

NP 001552.2

This protein is fused with a 6× His tag at C-terminus and has a calculated MW of 18.1 kDa. The protein migrates as 28-35 kDa in SDS-PAGE due to glycosylation. KDa

Human CellExp™ 4-1BB / TNFRSF9, Human recombinant - Additional Info

Other Names

TNFRSF9, 4-1BB, CD137, CDw137, ILA

Gene Source Source Assay&Purity Assay2&Purity2 Recombinant Target/Specificity CD137

Human

HEK 293 cells SDS-PAGE;≥92% N/A;≥92%

Yes

Application Notes

Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml

Format

Lyophilized

Storage


-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.

Human CellExp™ 4-1BB / TNFRSF9, Human recombinant - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Human CellExp™ 4-1BB / TNFRSF9, Human recombinant - Images





Human CellExp™ 4-1BB / TNFRSF9, Human recombinant - Background

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF.

responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with **TRAF**